Belite Bio CFO sells 6,200 ADS in planned trades

Belite Bio, Inc.'s Chief Financial Officer Hao-Yuan Chuang reported open-market sales of a total of 6,200 American depositary shares on April 9, 2026.

Rhea-AI Filing Summary

Belite Bio, Inc.'s Chief Financial Officer Hao-Yuan Chuang reported open-market sales of a total of 6,200 American depositary shares on April 9, 2026. The sales were executed in multiple trades at weighted average prices ranging from about $180.35 to $183.08, pursuant to a pre-established Rule 10b5-1 trading plan adopted on December 22, 2025. Following these transactions, Chuang directly holds 93,800 American depositary shares, which each represent one ordinary share of the company.

Insights

Equity markets analyst

CFO sells a small portion of holdings under a pre-set 10b5-1 plan, a routine liquidity event.

The Chief Financial Officer of Belite Bio, Inc. sold 6,200 American depositary shares in open-market transactions on April 9, 2026. All trades were executed under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance rather than timed opportunistically.

After these sales, the CFO continues to hold 93,800 American depositary shares directly, so the transactions represent only a small fraction of the reported position. The filing shows no derivative exercises or complex restructuring, and no remaining derivative positions are listed, suggesting a straightforward, routine disposition for portfolio or liquidity management.

Insider Trade Summary 10b5-1

Net Seller: 6,200 shares

Net Sell 4 txns

Insider Chuang Hao-Yuan

Role Chief Financial Officer

Sold 6,200 shs ($1.13M)

Type	Security	Shares	Price	Value
Sale	American depositary share	2,000	$180.3475	$361K
Sale	American depositary share	2,000	$181.395	$363K
Sale	American depositary share	1,909	$182.5782	$349K
Sale	American depositary share	291	$183.0813	$53K

Holdings After Transaction: American depositary share — 93,800 shares (Direct)

Footnotes (6)

1. F1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
2. F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/22/2025.
3. F3. Represents the weighted average price of shares sold at prices that ranged from $180.00 to $180.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
4. F4. Represents the weighted average price of shares sold at prices that ranged from $181.00 to $181.80. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
5. F5. Represents the weighted average price of shares sold at prices that ranged from $182.00 to $182.89. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
6. F6. Represents the weighted average price of shares sold at prices that ranged from $183.00 to $183.21. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 6,200 American depositary shares Holdings after sale: 93,800 American depositary shares Trade block 1 price: $180.3475 per share +4 more

7 metrics

Shares sold 6,200 American depositary shares Total non-derivative shares sold on April 9, 2026

Holdings after sale 93,800 American depositary shares Direct holdings of CFO following reported transactions

Trade block 1 price $180.3475 per share Weighted average price for 2,000 ADS sold

Trade block 2 price $181.3950 per share Weighted average price for 2,000 ADS sold

Trade block 3 price $182.5782 per share Weighted average price for 1,909 ADS sold

Trade block 4 price $183.0813 per share Weighted average price for 291 ADS sold

ADS to ordinary share ratio 1 ADS = 1 ordinary share Each ADS represents one ordinary share, par value US$0.0001

Key Terms

American depositary share, Rule 10b5-1 trading plan, weighted average price, open-market sale

4 terms

American depositary share financial

"Each American depositary share represents one ordinary share, par value US$0.0001 per share"

An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"Represents the weighted average price of shares sold at prices that ranged from $180.00 to $180.99"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale, transaction_code_description: Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Belite Bio (BLTE) report for its CFO?

Belite Bio reported that its Chief Financial Officer, Hao-Yuan Chuang, sold 6,200 American depositary shares in open-market transactions. The sales occurred on April 9, 2026, and were executed as multiple trades at different prices on that date.

How many Belite Bio (BLTE) shares did the CFO sell and at what prices?

The CFO sold 6,200 American depositary shares in total. Individual trade blocks were priced at weighted averages around $180.35, $181.40, $182.58, and $183.08, reflecting sales within narrow price ranges between $180.00 and $183.21.

Was the Belite Bio (BLTE) CFO’s share sale part of a Rule 10b5-1 plan?

Yes. The filing states the CFO’s sales were effected under a Rule 10b5-1 trading plan adopted on December 22, 2025. Such plans pre-schedule trades, aiming to separate routine diversification or liquidity needs from discretionary market-timing decisions.

How many Belite Bio (BLTE) shares does the CFO still own after these transactions?

Following the reported sales, the CFO directly holds 93,800 American depositary shares. This indicates that the 6,200 shares sold on April 9, 2026 represent only a small portion of the overall reported holding in Belite Bio.

What type of security did the Belite Bio (BLTE) CFO trade in this Form 4?

The CFO traded American depositary shares, each representing one ordinary share of Belite Bio with a par value of US$0.0001. These ADSs allow investors to hold an interest in the company’s ordinary shares through a U.S.-traded instrument.

Were Belite Bio (BLTE) derivatives or options involved in this insider transaction?

No derivatives or options are reported in this Form 4. All transactions relate to non-derivative American depositary shares, and the derivative section of the summary is empty, indicating no option exercises or other derivative activity in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/13/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chuang Hao-Yuan

(Last) (First) (Middle)

12750 HIGH BLUFF DRIVE, SUITE 475

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American depositary share(1)	04/09/2026		S(2)		2,000	D	$180.3475(3)	98,000	D
American depositary share(1)	04/09/2026		S(2)		2,000	D	$181.395(4)	96,000	D
American depositary share(1)	04/09/2026		S(2)		1,909	D	$182.5782(5)	94,091	D
American depositary share(1)	04/09/2026		S(2)		291	D	$183.0813(6)	93,800	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/22/2025.

3. Represents the weighted average price of shares sold at prices that ranged from $180.00 to $180.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

4. Represents the weighted average price of shares sold at prices that ranged from $181.00 to $181.80. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

5. Represents the weighted average price of shares sold at prices that ranged from $182.00 to $182.89. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

6. Represents the weighted average price of shares sold at prices that ranged from $183.00 to $183.21. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

	/s/ Hao-Yuan Chuang	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)